PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis by Yang, L. C. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2014
PKM2 regulates the Warburg effect and promotes
HMGB1 release in sepsis
L. C. Yang
M. Xie
M. H. Yang
Y. Yu
S. Zhu
See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Emergency Medicine Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.
Recommended Citation
Yang L, Xie M, Yang M, Yu Y, Zhu S, Lotze M, Billiar T, Wang H, Cao L, Tang D, . PKM2 regulates the Warburg effect and promotes
HMGB1 release in sepsis. . 2014 Jan 01; 5():Article 563 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/
563. Free full text article.
Authors
L. C. Yang, M. Xie, M. H. Yang, Y. Yu, S. Zhu, M. T. Lotze, T. R. Billiar, H. C. Wang, L. Z. Cao, D. L. Tang, and
+2 additional authors
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/563
PKM2 Regulates the Warburg Effect and Promotes HMGB1 
Release in Sepsis
Liangchun Yang1, Min Xie1, Minghua Yang1, Yan Yu1, Shan Zhu1, Wen Hou2, Rui Kang2, 
Michael Lotze2, Timothy R. Billiar2, Haichao Wang3, Lizhi Cao1,*, and Daolin Tang2
1Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan 
410008, People’s Republic of China
2Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, USA
3Laboratory of Emergency Medicine, The Feinstein Institute for Medical Research, Manhasset, 
New York 11030, USA
Abstract
Increasing evidence suggests the important role of metabolic reprogramming in the regulation of 
the innate inflammatory response, but the underlying mechanism remains unclear. Here, we 
provide evidence to support a novel role for the pyruvate kinase M2 (PKM2)-mediated Warburg 
effect, namely aerobic glycolysis, in the regulation of high mobility group box 1 (HMGB1) 
release. PKM2 interacts with hypoxia-inducible factor 1α (HIF1α) and activates the HIF-1α-
dependent transcription of enzymes necessary for aerobic glycolysis in macrophages. Knockdown 
of PKM2, HIF1α, and glycolysis-related genes uniformly decreases lactate production and 
HMGB1 release. Similarly, a potential PKM2 inhibitor, shikonin, reduces serum lactate and 
HMGB1 levels and protects mice from lethal endotoxemia and sepsis. Collectively, these findings 
shed light on a novel mechanism for metabolic control of inflammation by regulating HMGB1 
release and highlight the importance of targeting aerobic glycolysis in the treatment of sepsis and 
other inflammatory diseases.
Introduction
Severe sepsis and septic shock represent a major clinical problem and are the leading causes 
of death in patients within intensive care units worldwide1. This medical problem results 
from an exuberant and excessive host response associated with a deleterious and non-
resolving systemic inflammatory response syndrome, often caused by Gram-negative 
bacterial infection2. As the major component of Gram-negative bacteria, lipopolysaccharide 
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(LPS) can induce the secretion and release of multiple proinflammatory cytokines such as 
tumor necrosis factor-α (TNF-α)3, interleukin-1β (IL-1β)4, and high mobility group box 1 
(HMGB1)5. In contrast to early proinflammatory cytokines (e.g., TNF-α and IL-1β), 
HMGB1 is released in a delayed manner and functions as a late mediator of lethal sepsis5 
and thus as a therapeutic target has a wider time window for clinical intervention6.
In resting cells, most of the HMGB1 resides in the nucleus and functions as a DNA 
chaperone to regulate chromosomal structure and DNA biology7. When actively secreted by 
immune cells or passively leaked from necrotic or injured cells5,8,9, HMGB1 functions as a 
damage-associated molecular pattern to mediate innate immune responses10. The secretion 
of HMGB1 from activated immune cells is a highly-regulated process involving multiple 
steps and mechanisms. For instance, post-transcriptional modification (e.g., acetylation) in 
the nuclear localization signal promotes HMGB1 translocation from the nucleus to the 
cytoplasm11. Subsequently, secretory lysosome-mediated exocytosis and other unknown 
pathways facilitate HMGB1 release into the extracellular space12. Therefore, a more 
comprehensive understanding of the mechanisms underlying the regulation of HMGB1 
release by activated immune cells may ultimately lead to better treatments for patients with 
various inflammation-associated diseases13.
Metabolism includes processes in which biochemicals are degraded to produce energy (in 
the form of adenosine triphosphate). Intermediate metabolites may serve as signaling 
molecules to regulate cellular processes. This metabolism-driven reprogramming dictates 
the progression of many cellular functions and even cellular fate. For instance, tumor cells 
can strategically generate adenosine triphosphate through aerobic glycolysis (in addition to 
oxidative phosphorylation), even when oxygen is abundant14, enabling exaggerated tumor 
cell proliferation. This phenomenon has been termed the “Warburg Effect” and represents 
one of the key hallmarks of cancer15.
Growing evidence suggests that activated immune cells (e.g., macrophages, dendritic cells, 
and T cells) also have the ability to switch from oxidative phosphorylation to aerobic 
glycolysis in a fashion similar to tumor cells. This alteration may contribute to the regulation 
of innate immune functions16–19 and represents a novel target for inflammatory diseases. 
One key mediator of the Warburg effect is the transcription factor hypoxia inducible factor 
1α (HIF1α), a master regulator of metabolism that is upregulated in response to low oxygen 
or hypoxia20. Remarkably, a bacterial constituent, LPS, can also induce a switch from 
oxidative phosphorylation to aerobic glycolysis in dendritic cells and macrophages21–23 and 
consequently results in cell activation and release of proinflammatory cytokines, including 
IL-1β21–23.
Although the Warburg effect similarly occurs in activated macrophages, its possible role in 
the regulation of HMGB1 release is unknown. In the current study, we demonstrate that 
pyruvate kinase M2 (PKM2), a protein kinase and transcriptional coactivator, functions as 
an essential mediator of aerobic glycolysis24 and an important regulator of HMGB1 release 
in activated macrophages. Our findings shed light on a novel mechanism for metabolic 
control of inflammation by regulating HMGB1 release and highlight the possibility of 
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targeting the switch to aerobic glycolysis in the treatment of sepsis and other inflammatory 
diseases.
Results
Glycolysis promotes HMGB1 release
To investigate whether aerobic glycolysis plays a role in the regulation of HMGB1 release, 
we used a glucose analog, 2-deoxy-d-glucose (2-DG), a widely-used competitive inhibitor of 
the first hexokinase of the glycolytic pathway. 2-DG is phosphorylated by hexokinase to 2-
DG-P, which cannot be further metabolized by phosphoglucose isomerase. 2-DG (IC50 ≈ 1 
mM) significantly inhibited the LPS-induced switch from oxidative phosphorylation (as 
measured by oxygen consumption rate [OCR]) to glycolysis (as measured by extracellular 
acidification rate [ECAR]) in a concentration-dependent manner (Fig. 1a). In parallel, 2-DG 
treatment also concentration-dependently inhibited the release of early (e.g., IL-1β at two 
hours) and late (e.g., HMGB1 at 24 hours) mediators in LPS-stimulated macrophages (Fig. 
1b and 1c). Several immunoregulatory cytokines such as TNF-α5 and IFN-γ25 can induce 
HMGB1 release in macrophages. Similarly, 2-DG also inhibited TNF-α and IFN-γ-induced 
HMGB1 release in macrophages (Fig. 1d), suggesting a general role for glycolysis in the 
regulation of HMGB1 release. Although 2-DG significantly inhibited LPS-induced 
upregulation of IL-1β mRNA (Fig. 1e), it did not affect the HMGB1 mRNA levels in 
response to LPS, TNF-α, and IFN-γ in macrophages (Fig. 1f). These results are consistent 
with those from previous reports; namely, LPS induced IL-1β release in macrophages 
through transcriptional-dependent mechanisms, whereas LPS induced HMGB1 release in 
macrophages through transcriptional-independent mechanisms5,22. Collectively, our results 
therefore indicate a possible role for aerobic glycolysis in the regulation of HMGB1 release 
through post-transcriptional mechanisms.
PKM2 is required for active HMGB1 release
The M2 isoform of PKM2 catalyzes the final and rate-limiting reaction step of the glycolytic 
pathway and functions as the central regulator of cancer metabolism via regulating the 
Warburg effect26. It remains unclear, however, whether PKM2 is also important for the 
Warburg effect in activated innate immune cells. Surprisingly, LPS induced a time-
dependent increase in the protein and mRNA levels of PKM2 (Fig. 2a and 2b), but not 
PKM1 in macrophages (Fig. 2a), suggesting a possible role for PKM2 in the regulation of 
the Warburg effect as well as HMGB1 release. To test this possibility, a target-specific 
shRNA against PKM2 was transfected into RAW 264.7 macrophages. The transfection of 
PKM2-shRNA led to a significant decrease in PKM2 (Fig. 2a and 2b), but not PKM1 protein 
levels (Fig. 2a). In parallel, the knockdown of PKM2 was associated with a decrease in LPS-
induced glycolysis (Fig. 2c) and accompanying reduction of HMGB1 release (Fig. 2d). 
Treatment with a potential PKM2 inhibitor, shikonin27, also resulted in significant inhibition 
of LPS-, TNF-α-, and IFN-γ-induced HMGB1 release (Fig. 2e). Furthermore, knockdown of 
PKM2 by lentiviral shRNA in primary bone marrow macrophages (BMMs) inhibits LPS-, 
TNF-α-, and IFN-γ-induced HMGB1 release (Fig. 2f and 2g). Collectively, these results 
support an important role for PKM2-mediated glycolysis in the regulation of HMGB1 
release in activated macrophages.
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PKM2-mediated HIF1α activation is required for HMGB1 release
In cancer cells, PKM2 physically interacts with HIF1α in the nucleus and activates the 
transcription of glycolysis-related genes such as GLUT1 (glucose transporter 1, which 
increases glucose uptake), LDHA (lactate dehydrogenase A, which increases lactate 
production), and PDK1 (pyruvate dehydrogenase kinase 1, which blocks the entry of 
pyruvate into the tricarboxylic acid cycle)28. In LPS-stimulated RAW264.7 cells and 
primary BMMs, the interaction between PKM2 and HIF1α was markedly elevated, as 
determined by immunoprecipitation assays (Fig. 3a). However, the knockdown of PKM2 by 
RNAi impaired LPS-induced HIF1α transcriptional activation (Fig. 3b), as well as the 
consequent expression of GLUT1 (Fig. 3c), LDHA (Fig. 3d), and PDK1 mRNAs (Fig. 3e). 
Notably, the knockdown of PKM2 did not affect LPS-induced HIF1α protein expression 
(Fig. 3f), suggesting an important role of PKM2-HIF1α interaction in the regulation of the 
transcriptional activity, but not the stability of HIF1α protein in activated macrophages. To 
confirm the roles of HIF1α as well as its target glycolysis-related genes in the regulation of 
HMGB1 release, various shRNA constructs were transfected into cultured macrophages. 
Interestingly, knockdown of HIF1α (Fig. 3g), GLUT1 (Fig. 3h), LDHA (Fig. 3i), and PDK1 
(Fig. 3i) by RNAi uniformly impaired LPS-induced HMGB1 release. Together, these 
findings suggest a novel role for PKM2-mediated HIF1α activation in the regulation of 
HMGB1 release by activated macrophages.
Lactate promotes HMGB1 acetylation and release
As the end product of glycolysis, lactate accumulated at increased levels (5–7 mM) in the 
culture medium of LPS-stimulated macrophages (Fig. 4a). In contrast, the knockdown of 
PKM2 and HIF1α prevented LPS-induced lactate accumulation in the culture medium (Fig. 
4a). To understand the role of lactate in the regulation of HMGB1 release, we tested whether 
supplementation of exogenous lactate could induce HMGB1 release. Indeed, exposure of 
macrophage cultures to lactate (5 mM for six hours) triggered a marked HMGB1 release 
without reducing cell viability (Fig.4b and 4c). The recently identified lactate receptor 
GPR8129 was responsible for this effect (Fig.4b and 4c). In addition, intermediate 
metabolites of glycolysis such as 3-phosphoglycerate (3PG), 2-phosphoglycerate (2PG), and 
phosphoenolpyruvate (PEP) can induce lactate production and HMGB1 release in 
macrophages (Fig. 4d). Acetylation is a post-translational modification that can promote 
HMGB1 cytoplasmic translocation and subsequent release in response to various 
inflammatory stimuli as well as hypoxia11,30. Lactate increased HMGB1 acetylation (Fig. 
4e), whereas LPS-induced HMGB1 acetylation was impaired by the knockdown of PKM2 
and HIF1α (Fig. 4f). To gain insight into the mechanisms underlying glycolysis-mediated 
HMGB1 hyperacetylation, we assayed the activity of histone deacetylases (HDACs) which 
have been shown to acetylate both histone and non-histone nuclear proteins, including 
HMGB111,30. Like LPS and HDAC inhibitors (e.g., trichostatin A [TSA]), lactate and PEP 
also decreased the activity of HDACs in macrophage cultures (Fig. 4g–j). Collectively, these 
findings suggest that LPS-induced lactate production from PKM2-mediated aerobic 
glycolysis may act as an inhibitory signal for HDAC activity, which in turn enables HMGB1 
hyperacetylation and subsequent release by LPS-stimulated macrophages.
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A previous study demonstrated that lactate stimulates Toll-like receptor (TLR)-4 signaling 
activation in macrophages31. In addition, HMGB1 can stimulate TNF-α release through 
TLR432. We demonstrated that HMGB1-neutralizing antibody significantly inhibits lactate-
induced TNF-α release (Fig. 4k). These findings suggest that lactate promotes macrophage 
activation via an autocrine HMGB1-dependent pathway.
Shikonin protects mice from endotoxic shock and sepsis
Given the capacity of the PKM2 inhibitor shikonin to attenuate LPS-induced IL-1β and 
HMGB1 release in vitro, we determined whether shikonin protects mice against lethal 
endotoxemia by inhibiting cytokine release. Repetitive administration of shikonin at −0.5, 
+12, and +24 hours following the onset of endotoxemia (5 mg kg−1 LPS, intraperitoneally 
[i.p.]) conferred significant protection against lethal endotoxemia (Fig. 5a) and 
simultaneously reduced the PKM2 activity in peritoneal macrophages (Fig. 5b) and the 
serum levels of lactate (Fig. 5c), IL-1β (Fig. 5d), and HMGB1 (Fig. 5e) in endotoxemic 
mice. All of these mice were observed for at least two weeks and no late deaths occurred. 
These findings suggest that shikonin does not merely delay animal lethality by attenuating 
the production of lactate and cytokines, but also provides long-lasting protection. Although 
endotoxemia is a useful animal model for investigating the complex network of cytokines, a 
more clinically relevant experimental model for sepsis is bacterial infection induced by cecal 
ligation and puncture (CLP). At +24, +48, +72 hours following the onset of sepsis, animals 
were given shikonin or vehicle i.p.. Shikonin rescued mice from CLP-induced lethal sepsis, 
even if given after the onset of sepsis (Fig. 5f). All of these mice were observed for at least 
two weeks and no late deaths occurred. The PKM2 activity in peritoneal macrophages (Fig. 
5g) and the serum levels of lactate (Fig. 5h) and HMGB1 (Fig. 5i) were significantly 
decreased in the group receiving shikonin treatment for CLP. Collectively, these data 
suggest that the PKM2 inhibitor shikonin protects against experimental lethal endotoxic 
shock and sepsis partly by inhibiting PKM2 activity, lactate production, and HMGB1 
release.
Discussion
To ensure a timely response to infection, effective innate recognition systems that rapidly 
detect various microbial products such as LPS have evolved in mammals. The effective 
recognition of pathogen associated molecular patterns by innate immune cells triggers the 
sequential release of early (e.g., TNF-α and IL-1β) and late (e.g., HMGB1) proinflammatory 
cytokines. Appropriate inflammatory responses facilitate innate immunity against infections, 
but excessive inflammation may also result in sepsis and even death1,2. The molecular 
mechanisms underlying the innate immune system response to LPS are not completely 
understood. In this study, we demonstrate that PKM2-mediated aerobic glycolysis 
contributes to macrophage activation and the resultant inflammatory response. As a co-
activator, PKM2 interacts with HIF-1α and activates the transcription of glycolysis-related 
genes, leading to excessive lactate production and HMGB1 hyperacetylation and its 
subsequent release. Moreover, genetic and/or pharmacological inhibition of PKM2 
significantly impairs LPS-induced HMGB1 release in macrophages and protects mice from 
lethal endotoxic shock and sepsis. These findings provide novel insight into the mechanisms 
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underlying the metabolic control of inflammation and highlight the importance of targeting 
aerobic glycolysis in the treatment of patients with sepsis and other inflammatory diseases.
The Warburg effect, first observed in various tumor cells, is also increasingly recognized as 
an essential regulator of innate and adaptive immunity. For instance, increased aerobic 
glycolysis contributes to the maturation of dendritic cells in response to TLR4, TLR2, and 
TLR9 ligands21 and influences the differentiation of both anti-inflammatory Treg cells and 
pro-inflammatory Th17 cells33,34. There are two major types of macrophages35: the classical 
M1 phenotype, which can be activated by LPS and IFN-γ to orchestrate proinflammatory 
responses, and the alternate M2 phenotype, which is activated by IL-4, IL-13, IL-10, and 
TGF-β to fulfill anti-inflammatory functions. LPS can induce the metabolic switch to 
aerobic glycolysis only in M1 macrophages, which contributes to transcriptional expression 
and release of early proinflammatory cytokines (e.g., IL-1β)22. In this study, we found that 
increased aerobic glycolysis also contributes to LPS-induced release of late mediators (e.g., 
HMGB1) by modulating its post-translational modification (rather than transcriptional 
expression). It now appears that the Warburg effect can participate in the regulation of 
proinflammatory cytokines at both the transcriptional and post-transcriptional levels.
Although PKM2 is expressed at extremely low levels (if any at all) in quiescent and 
normally differentiated cells, its expression levels are markedly upregulated in rapidly 
proliferating tumor cells as well as activated macrophages. Elevated PKM2 expression in 
cancer cells26 and activated immune cells enables the metabolic switch from oxidative 
phosphorylation to aerobic glycolysis. In cancer cells, PKM2 contributes to the Warburg 
effect by interacting and activating HIF-1α to induce the expression of glycolytic genes28. 
Here, we demonstrate that PKM2 fulfills similar functions by interacting with HIF1α to 
regulate the expression of LPS-induced glycolytic genes and release of proinflammatory 
cytokines in macrophages. Consistently, the knockdown of PKM2, HIF1α, as well as 
aerobic glycolysis-related genes (e.g., GLUT1, LDHA, and PDK1) significantly impaired 
LPS-induced HMGB1 release, suggesting an important role of the PKM2-HIF1α glycolysis 
pathway in the regulation of HMGB1 release by activated macrophages.
Intriguingly, it has been suggested that hyperglycemia aggravates LPS-induced HMGB1 
release, whereas insulin can decrease serum HMGB1 levels in septic animals36, implying a 
possible role of glucose metabolism in the regulation of HMGB1 release. The mechanisms 
underlying the regulation of PKM2 expression in macrophages remains a subject of future 
investigation. In cancer cells, however, the expression of PKM2 is controlled by several 
transcription factors such as Sp137, NF-κB38, and Myc39, as well as HIF1α28. In addition, 
activation of the extracellular signal-regulated kinase (ERK) is required for PKM2 
expression and nuclear translocation during aerobic glycolysis40. Given the essential role of 
ERK in regulating active HMGB1 secretion41, elucidating the mechanism underlying the 
regulation of PKM2 upregulation in activated immune cells will be important.
Hypoxia and inflammation are often intimately associated under various conditions. 
Hypoxia is not only a prominent feature in inflamed and injured tissues, but also an effective 
inducer of inflammatory responses42,43. Under hypoxic conditions, HIF1α, the master 
regulator of the cellular response to hypoxia, can escape degradation by the ubiquitin-
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proteasome pathway, thereby accumulating at high levels44. Similarly, bacterial products 
(e.g., LPS)45 and proinflammatory cytokines (e.g., TNF-α and IFN-γ)46,47 can also stabilize 
HIF1α and activate relevant signaling pathways, even under normoxic conditions. In the 
present study, we found that knockdown of HIF1α impairs LPS-induced HMGB1 release by 
macrophages under normoxic conditions. Similarly, others have found that conditional 
knockout of HIF1α in myeloid cells (including macrophages) decreased inflammatory 
responses in vivo48 and protected animals against LPS-induced lethality49.
Activated macrophages/monocytes acetylate HMGB1 at its nuclear localization sequences, 
leading to sequestration of HMGB1 within cytoplasmic vesicles and subsequent release into 
the extracellular milieu. Extracellular HMGB1 functions as a late mediator of lethal 
endotoxemia and sepsis because HMGB1-neutralizing antibodies or inhibitors reverse the 
course of established experimental sepsis even when these antidotes are given up to 24 hours 
after induction of experimental sepsis5,50,51. These findings support the idea of HMGB1 as a 
promising therapeutic target to allow rescue from lethal sepsis. It is thus important to fully 
understand the intricate mechanisms underlying the regulation of HMGB1 release under 
relevant pathological conditions. Our present study reveals a crucial role for the PKM2 
pathway in the regulation of HMGB1 release and suggests another possible therapeutic 
target for sepsis. Indeed, a potential PKM2 inhibitor27, shikonin, conferred significant 
protection against lethal endotoxemia and sepsis partly by attenuating systemic 
accumulation of lactate and proinflammatory cytokines. Of note, increased serum lactate 
levels have been suggested as a biomarker of organ failure and mortality in patients with 
sepsis, trauma, and other critical illnesses52–54. Our findings that lactate can effectively 
stimulate macrophages to release HMGB1 provide a logical explanation for lactate clearance 
as a therapy for sepsis and other inflammatory diseases. As a component of Chinese herbal 
medicine, shikonin also has antioxidant properties55 and has been tested for efficacy in the 
treatment of microbial infections and cancer in experimental and clinical settings56. It is 
essential to determine whether other HMGB1 inhibitors (e.g., EGCG, tanshinone, 
carbenoxolone, and quercetin) confer protection against lethal sepsis similarly by inhibiting 
the PKM2-mediated Warburg effect in innate immune cells.
Collectively, our findings reveal a novel PKM2-dependent mechanism for the metabolic 
control of inflammation. Upregulation of PKM2 expression enables a metabolic switch to 
aerobic glycolysis, leading to excessive production of lactate. By inhibiting HDAC 
activity57, lactate in turn increases HMGB1 hyperacetylation, translocation to the cytoplasm, 
and subsequent release into the extracellular milieu. Thus, novel therapeutic strategies 
targeting aerobic glycolysis for the treatment of patients with sepsis and other inflammatory 
diseases are in order.
Methods
Reagents
LPS (Escherichia coli LPS 0111:B4; #L4391), 2DG (#D8375), TSA (#8552), 3-
phosphoglycerate (#P8877), 2-phosphoglycerate (#19710), and phosphoenolpyruvate 
(#860077) were obtained from Sigma (St. Louis, MO, USA). Shikonin (#CAS 517-89-5) 
was obtained from EMD Millipore Corporation (Billerica, MA, USA). Mouse TNF-α 
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(#410-MT-010) and IFN-γ (485-MI-100) were obtained from R&D Systems (Minneapolis, 
MN, USA). Mouse anti-HMGB1 2G7 neutralizing antibody was a generous gift from Kevin 
J. Tracey (The Feinstein Institute for Medical Research, Manhasset, NY, USA)32.
Cell culture
Murine macrophage-like RAW 264.7 cells were obtained from the American Type Culture. 
Mouse peritoneal and bone marrow macrophages were isolated from Balb/C mice58,59. 
These cells were cultured in Dulbecco's Modified Eagle's Medium (supplemented with 10% 
heat-inactivated fetal bovine serum and 100 unites of penicillin and 100µg ml−1 
streptomycin) at 37 °C, 95% humidity, and 5% CO2.
Animal model of endotoxemia and sepsis
This study was approved by the Xiangya Hospital Institutional Ethics Committee and 
performed in accordance with Association for Assessment and Accreditation of Laboratory 
Animal Care guidelines (http://www.aaalac.org/). Endotoxemia was induced in Balb/C mice 
(male, seven to eight weeks old, 20–25 g) by i.p. injection of bacterial endotoxin (LPS, 5 
mg/kg)5,51. Sepsis was induced in male Balb/C mice (male, 7–8 weeks old, 20–25 g) by 
cecal ligation and puncture5,51. Shikonin was dissolved in vehicle (10% DMSO, 20% 
Cremophor:ethanol [3:1] and 70% phosphate buffered saline) and administered i.p. to mice 
at the indicated time points. Blood was collected at indicated time points, allowed to clot for 
two hours at room temperature, and then centrifuged for 15 minutes at 1,500×g. Serum 
samples were stored at −20°C before analysis. Mortality was recorded for up to two-three 
weeks after the onset of lethal endotoxemia or sepsis to ensure that no additional late deaths 
occurred.
Cytokine measurements
Commercially available enzyme linked immunosorbant assay (ELISA) kits were used to 
measure the concentrations of HMGB1 (Shino Test Corporation, Tokyo, Japan, #ST51011), 
IL-1β (R&D Systems, Minneapolis, MN, USA, # MLB00C) and TNF-α (R&D Systems, 
Minneapolis, MN, USA, # MTA00B) in serum or the culture medium according to the 
manufacturer’s instructions.
Activity assay
Lactate in serum or the culture medium was measured with colorimetric L-Lactate Assay Kit 
(Abcam, Cambridge, MA, USA, #ab65331) according to the manufacturer’s instructions. 
HDAC activity was measured with the fluorometric HDAC Activity Assay kit (Abcam, 
#ab156064) according to the manufacturer’s instructions. HIF1α DNA binding activity in 
nuclear extracts was measured with HIF1α Transcription Factor Assay Kit (Cayman, Ann 
Arbor, MI, USA, #10006910) according to the manufacturer’s instructions. PKM2 activity 
was measured by a lactate dehydrogenase-coupled enzyme assay27,60. The assay was carried 
out with 1 µg of cell lysates with an enzyme buffer (50 mM tris-HCl [pH 7.5], 100 mM KCl, 
10 mM MgCl2, 0.9 mM adenosine diphosphate, 0.6 mM phosphoenolpyruvate, 0.12 mM β-
nicotinamide adenine dinucleotide and 4.8 U ml−1 lactate dehydrogenase). Enzyme activity 
can be measured at 340 nm absorbance by spectrophotometry.
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RNAi
All shRNA constructs were in the pLKO.1 backbone (Sigma). Transfection with indicated 
shRNA (Supplementary Table 1) and control empty shRNA (#SHC001) from Sigma were 
performed using FuGENE® HD Transfection Reagent (Roche Applied Science) or 
MISSION shRNA Lentiviral Transduction (Sigma) according to the manufacturer’s 
instructions.
Western blot analysis
After extraction, proteins in cell lysates were first resolved by SDS-polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membrane and subsequently incubated 
with the primary antibody. The antibodies to HMGB1 (#ab18256; 1:1000) and HIF1α 
(#ab16066; 1:1000) were obtained from Abcam (Cambridge, MA, USA). The antibodies to 
PKM1 (#7067; 1:1000), PKM2 (#4053; 1:1000), acetylated-Lysine (#9441; 1:1000), and 
actin (#3700; 1:1000) were obtained from Cell Signaling Technology (Danvers, MA, USA). 
The antibody to GPR81 (#SAB1300089; 1:200) was obtained from Sigma (St. Louis, MO, 
USA).). After incubation with peroxidase-conjugated secondary antibodies, the signals were 
visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA, # 32106) according 
to the manufacturer's instruction. The relative band intensity was quantified using the Gel-
pro Analyzer® software (Media Cybernetics, Bethesda, MD, USA).
Quantitative real time polymerase chain reaction
Total RNA was extracted using TRI reagent (Sigma) according to the manufacturer’s 
instructions. First-strand cDNA was synthesized from 1 µg of RNA using the iScript cDNA 
Synthesis kit (Bio-Rad, Hercules, CA). cDNA from various cell samples were amplified by 
real-time quantitative PCR with specific primers (Supplementary Table 2).
Immunoprecipitation analysis
Cells were lysed at 4°C in RIPA buffer (Millipore, Billerica, MA, USA). Prior to 
immunoprecipitation, samples containing equal amounts of proteins were pre-cleared with 
Protein A sepharose (Millipore) and subsequently incubated with various irrelevant IgG or 
specific antibodies [PKM2 (#4053; 2 µg ml−1) and HMGB1 (#ab18256; 2 µg ml−1)] in the 
presence of protein A sepharose beads. The beads were washed three times with RIPA 
buffer and the immune complexes were eluted from the beads and subjected to SDS-PAGE 
and immunoblot analysis as previously described61,62.
Oxidative phosphorylation and glycolysis assay
Cellular OXPHOS and glycolysis were monitored using the Seahorse Bioscience 
Extracellular Flux Analyzer (XF24, Seahorse Bioscience Inc., North Billerica, MA, USA) 
by measuring the OCR (indicative of respiration) and ECAR (indicative of glycolysis)63,64. 
Briefly, 30,000–50,000 cells were seeded in 24-well plates designed for XF24 in 150 µl of 
appropriate growth media and incubated overnight. Prior to measurements, cells were 
washed with unbuffered media once, then immersed in 675 µl unbuffered media and 
incubated in the absence of CO2 for one hour. OCR and ECAR were then measured in a 
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typical eight-minute cycle of mix (two-four minutes), dwell (two minutes), and measure 
(two-four minutes) as recommended by Seahorse Bioscience.
Statistical analysis
Data are expressed as means ± SEM of two or three independent experiments. Significance 
of differences between groups was determined by ANOVA LSD test. The Kaplan-Meier 
method was used to compare the differences in mortality rates between groups. A p-value < 
0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Glycolytic inhibitor 2DG attenuates HMGB1 release by activated macrophages
(a–c) Murine RAW 264.7 macrophage cell line and primary peritoneal macrophages were 
pretreated with 2DG for three hours and then stimulated with lipopolysaccharide (LPS) (100 
ng ml−1) for two-24 hours. The oxygen consumption rates (OCR, indicative of oxidative 
phosphorylation) and extracellular acidification rates (ECAR, indicative of glycolysis) were 
monitored at 24 hours using the Seahorse Bioscience Extracellular Flux Analyzer (a). The 
levels of secreted IL-1β at two hours (b) and HMGB1 at 24 hours (c) in the cell culture 
medium were measured by ELISA (n=3, means ± SEM, *P < 0.05 by ANOVA LSD test). 
(d) 2DG (2 mM) inhibits TNF-α (5 ng ml−1) and IFN-γ (10 ng ml−1)-induced HMGB1 
release at 24 hours (n=3, means ± SEM, *P < 0.05 by ANOVA LSD test). (e) IL-1β mRNA 
in RAW 264.7 macrophages after treatment with LPS (100ng/ml) for two hours with or 
without 2DG (2 mM) (n=3, means ± SEM, *P < 0.05 by ANOVA LSD test). (f) HMGB1 
mRNA in RAW264.7 macrophages after treatment with LPS (100 ng ml−1), TNF-α (5 ng 
ml−1), and IFN-γ (10 ng ml−1) for 24 hours with or without 2DG (2 mM) (n=3, means ± 
SEM, *P < 0.05 by ANOVA LSD test). AU= arbitrary units.
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Figure 2. Upregulated PKM2 promotes aerobic glycolysis and HMGB1 release in activated 
macrophages
(a–d) RAW 264.7 cells were transfected with or without indicated shRNA for 48 hours and 
then stimulated with LPS (100 ng ml−1) for six-24 hours. The level of indicated protein (a), 
mRNA (b), ECAR (c), and HMGB1 release (d) were assayed as described in the methods 
(n=3, means ± SEM, *P < 0.05 by ANOVA LSD test). AU= arbitrary units. (e) RAW 264.7 
cells were pretreated with shikonin (5 µM) for three hours and then stimulated with 
lipopolysaccharide (LPS) (100 ng ml−1), TNF-α (5 ng ml−1), and IFN-γ (10 ng ml−1) for 24 
hours. HMGB1 release was assayed by ELISA (n=3, means ± SEM, *P < 0.05 by ANOVA 
LSD test). (f, g) Bone marrow macrophages (BMMs) were transfected with or without 
indicated shRNA for 48 hours and then stimulated with LPS (100 ng ml−1), TNF-α (5 ng 
ml−1), and IFN-γ (10 ng ml−1) for 24 hours. The mRNA levels of PKM2 (f) and HMGB1 
release (g) were assayed (n=3, means ± SEM, *P < 0.05 by ANOVA LSD test). AU= 
arbitrary units.
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Figure 3. PKM2-mediated HIF1α activation is required for HMGB1 release in activated 
macrophages
(a) RAW 264.7 cells (RAW) and bone marrow macrophages (BMMs) were stimulated with 
lipopolysaccharide (LPS) (100 ng ml−1) for 24 hours. The interaction between PKM2 and 
HIF1α was assayed by immunoprecipitation (IP) and immune-blot (IB). (b–f) RAW 264.7 
cells and BMMs were transfected with control shRNA or PKM2 shRNA for 48 hours and 
then stimulated with LPS (100 ng ml−1) for six-24 hours. The mRNA levels of indicated 
genes (b–e) were assayed by real time PCR (n=3, means ± SEM, *P < 0.05 by ANOVA 
LSD test). AU= arbitrary units. The protein level of HIF1α was assayed by Western blot (f). 
(g–j) RAW 264.7 cells were transfected with indicated shRNA for 48 hours and then 
stimulated with LPS (100 ng ml−1) for 24 hours. The mRNA levels of indicated genes were 
assayed by real time PCR. In parallel, the extracellular levels of HMGB1 were assayed by 
ELISA (n=3, means ± SEM, *P < 0.05 by ANOVA LSD test). AU= arbitrary unit.
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Figure 4. Lactate, a product of aerobic glycolysis, promotes HMGB1 acetylation and release
(a) RAW 264.7 cells were transfected with indicated shRNA for 48 hours and then 
stimulated with lipopolysaccharide (LPS) (100 ng ml−1) for six-24 hours. The lactate level 
in the culture medium was assayed (n=3, means ± SEM, *P < 0.05 versus control shRNA 
group by ANOVA LSD test). (b–c) RAW 264.7 cells were transfected with GRP81 shRNA 
and control shRNA for 48 hours and then stimulated with lactate (5 mM) for six hours. 
GRP81 expression (b), cell viability (c), and HMGB1 release (c) were assayed (n=3, means 
± SEM, *P < 0.05 by ANOVA LSD test). (d) RAW 264.7 cells were stimulated with 3-
phosphoglycerate (3PG, 2 mM) and 2-phosphoglycerate (2PG, 2 mM), 
phosphoenolpyruvate (PEP, 2 mM) for six hours and levels of lactate and HMGB1 release 
were assayed (n=3, means ± SEM, *P < 0.05 versus untreated group by ANOVA LSD test). 
(e) RAW 264.7 cells were stimulated with lactate (5 mM) for six hours and levels of 
acetylated HMGB1 were assayed. (f) RAW 264.7 cells were stimulated with LPS (100 ng 
ml−1) for 24 hours and the levels of acetylated HMGB1 were assayed. (g) RAW 264.7 cells 
were stimulated with LPS (100 ng ml−1), lactate (5 mM) and PEP (2 mM) for 24 hours. 
Histone deacetylase (HDAC) activity was assayed (n=3, means ± SEM, *P < 0.05 versus 
untreated group by ANOVA LSD test). (h-j) RAW 264.7 cells were stimulated with 
Trichostatin A (TSA) (2 µM) and/or LPS (100 ng ml−1) for 24 hours. HDAC activity (h) and 
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acetylated HMGB1 (i) and HMGB1 release (j) were assayed (n=3, means ± SEM, *P < 0.05 
by ANOVA LSD test). (k) RAW 264.7 cells were stimulated with lactate (5 mM, six hours) 
with or without anti-HMGB1 neutralizing antibody (2 µg ml−1) and levels of TNF-α release 
were assayed (n=3, means ± SEM, *P < 0.05 by ANOVA LSD test).
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Figure 5. A potential PKM2 inhibitor shikonin protects mice from lethal endotoxemia and sepsis
(a) Mice (n=20 group−1) were injected with a single dose of shikonin (8 mg kg−1), followed 
30 minutes later by an infusion of endotoxin (LPS, 5 mg kg−1, intraperitoneally), and were 
then re-treated with shikonin 12 and 24 hours later. The Kaplan-Meyer method was used to 
compare the differences in survival rates between groups (*, P<0.05). (b–e) In parallel 
experiments, the PKM2 activity in peritoneal macrophages (b) and serum levels of lactate 
(c), IL-1β (d), and HMGB1 (e) at indicated time points were measured (n=3–5 animals 
group−1, values are mean ± SEM, *, P<0.05 by ANOVA LSD test). (f) The cecal ligation 
and puncture (CLP) technique was used to induce intraabdominal sepsis in mice (n=20 
group−1). Repeated administration of shikonin (8 mg kg−1) at 24, 48, and 72 hours after CLP 
significantly increased survival, as compared with vehicle group (*, P<0.05), as measured 
by Kaplan-Meyer test. (g–i) In parallel, the PKM2 activity in peritoneal macrophages (g) 
and serum levels of lactate (h) and HMGB1 (i) at indicated time points were measured 
(n=3–5 animals group−1, values are mean ± SEM, *, P<0.05 by ANOVA LSD test).
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